The American corporation of Allerg...

The American corporation of Allergy, Asthma and Immunology has issued guidelines in succession allergen immunotherapy. The recommendations are available online at www.jcaai.org/Param/ immunotherapy/index.htm.

According to the guidelines, patients who have symptoms of allergic rhinitis or allergic asthma and demonstrate specific IgE antibodies after outlook to allergic triggers (e.g., pollen mold dust mites, miff dander, insect stings), whose symptoms are not adequately controll on medications, and who want to avoid or resolve into long-term medication use should be considered for allergen immunotherapy. The decision to begin immunotherapy hangs on the degree to which symptoms can be reduc from avoidance and medication, the amount and prototype of medication required to dominion government symptoms, and the adverse imports of the medications.

Venom immunotherapy should be considered in patients with a history of systemic reaction to a Hymenoptera sting, especially if the reaction was associated with respiratory or cardiovascular symptoms.

COPYRIGHT 2003 American Academy of Family Physicians

COPYRIGHT 2003 Gale Group